Cell BioEngines LLC - Powering Cellular Medicine
About Us
Technology
Our Pipeline
Our Team
News
Careers
Cell BioEngines LLC - Powering Cellular Medicine
About Us
Technology
Our Pipeline
Our Team
News
Careers
More
  • About Us
  • Technology
  • Our Pipeline
  • Our Team
  • News
  • Careers
  • About Us
  • Technology
  • Our Pipeline
  • Our Team
  • News
  • Careers

Our Team

Our team comprises of accomplished scientist-entrepreneurs with novel foresight to imagine innovative solutions and products. 

About 'Ajay'

Ajay Vishwakarma, DMD, MSC, MBA

Dr. Ajay Vishwakarma is the Founder and Chief Executive Officer (CEO) of Cell BioEngines. He is a scientist by training and has been active in the field of biotech for more than 10 years. Most recently, Dr. Ajay was the regional manager of Agilent's (NYSE:A) Cell Analysis New England Division during which he introduced the company's cell 

Dr. Ajay Vishwakarma is the Founder and Chief Executive Officer (CEO) of Cell BioEngines. He is a scientist by training and has been active in the field of biotech for more than 10 years. Most recently, Dr. Ajay was the regional manager of Agilent's (NYSE:A) Cell Analysis New England Division during which he introduced the company's cell analysis portfolio products for cell and gene therapy discovery and development in the academic and corporate market. Prior to that, he developed commercial roadmaps for advanced therapy medicinal products (ATMPs) manufacturing in stem cell biobanking industry.


Dr. Ajay earned his doctor’s degree from MUHS India, master’s in tissue engineering and regenerative medicine from Cardiff University, UK, and post-doctorate from Harvard University and Massachusetts Institute of Technology studying immunomodulatory mesenchymal stem cells and macrophage engineering. 


Dr. Ajay performed his PhD research at MGH Center for Cancer Immunotherapy, Harvard Medical School and Broad Institute of MIT and Harvard wherein he developed single cell genomic strategies to understand human tumor immunology, identifying functional immune cell subtypes within the tumor microenvironment of  cancer patients. Next to his research interests, he holds a MBA degree in Finance from University of Massachusetts Boston and is involved in the development of novel immunotherapeutics in biotech and in venture capital.

BOOKS

Copyright © 2025 Cell BioEngines, Inc - All Rights Reserved.

Powered by